105,756 Shares in Avanos Medical, Inc. $AVNS Acquired by Legal & General Group Plc

Legal & General Group Plc purchased a new stake in shares of Avanos Medical, Inc. (NYSE:AVNS) in the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 105,756 shares of the company’s stock, valued at approximately $2,631,000.

Several other large investors have also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC lifted its stake in shares of Avanos Medical by 132.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock worth $28,000 after acquiring an additional 1,423 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Avanos Medical by 969.3% in the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock worth $31,000 after buying an additional 2,307 shares during the period. Wexford Capital LP purchased a new stake in shares of Avanos Medical in the third quarter valued at $70,000. Longfellow Investment Management Co. LLC purchased a new stake in shares of Avanos Medical in the second quarter worth approximately $75,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Avanos Medical by 433.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock worth $77,000 after acquiring an additional 5,083 shares during the last quarter. 95.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AVNS has been the subject of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, July 20th. Zacks Research raised shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Friday, June 5th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Avanos Medical presently has a consensus rating of “Reduce”.

Avanos Medical Price Performance

Shares of NYSE AVNS opened at $24.99 on Friday. The firm’s 50-day moving average price is $24.97 and its 200-day moving average price is $21.76. Avanos Medical, Inc. has a 1-year low of $9.30 and a 1-year high of $25.49. The firm has a market capitalization of $1.17 billion, a P/E ratio of -15.52 and a beta of 1.57. The company has a current ratio of 2.48, a quick ratio of 1.40 and a debt-to-equity ratio of 0.11.

Avanos Medical Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.